Loading organizations...
Loading organizations...
Color Genomics has raised $45.0M across 1 funding round.
Key people at Color Genomics.
Color Genomics was founded in 2013 by Elad Gil (Co-founder) and Othman Laraki (Co-Founder & CEO).
Color Genomics has raised $45.0M in total across 1 funding round.
Color Genomics is a Burlingame, California-based healthcare technology company that provides accessible genetic testing and population-scale preventive care solutions. The company utilizes data science and proprietary software to assess hereditary risks for cancer and other conditions, selling its services directly to individuals, employers, unions, and health systems. To expand its broader cancer care and health initiatives, the organization has established strategic partnerships with major medical institutions such as MSK and UCSF. Backed by prominent investors including General Catalyst, Kindred Ventures, and BlackRock co-founder Susan Wagner, the enterprise reached a valuation exceeding $1 billion after securing over $60 million in early venture funding. As of February 2026, the company's stock traded publicly at $30.10 per share following a recent market adjustment. Color Genomics was founded in 2013 by Othman Laraki, Elad Gil, Taylor Sittler, and Nish Bhat.
Color Genomics was founded in 2013 by Elad Gil (Co-founder) and Othman Laraki (Co-Founder & CEO).
Color Genomics has raised $45.0M in total across 1 funding round.
Color Genomics's investors include Primitive Ventures, Tencent Holdings.
Key people at Color Genomics.
Color Genomics (now Color Health) is a precision medicine company that provides affordable, clinical-grade genetic testing and comprehensive cancer care programs. It builds products like genetic tests for hereditary cancer risks (e.g., BRCA1/BRCA2 and 17+ genes), heart conditions, medication response, and population-scale screening solutions, serving individuals, employers, health plans, unions, governments, and research programs like NIH's All of Us.[1][2][5] The company solves barriers to genetic information access—high costs, long wait times, and limited counseling—enabling early detection, personalized prevention plans, and proactive cancer management to reduce mortality.[1][2][3] With $482M in funding, $219.5M estimated annual revenue, and a $4.6B valuation (as of 2021), Color has served over 7 million patients, established a 50-state medical practice, and partnered globally across 100+ countries.[1][2]
Founded in 2013 by Othman Laraki (CEO) and others with tech backgrounds from Google, Dropbox, Pinterest, and Twitter, Color emerged to democratize clinical genomics amid expensive, inaccessible testing for cancer risks.[1][2][6] The idea crystallized in 2015 with the launch of an at-home genetic test for BRCA1, BRCA2, and 17 cancer-related genes, priced at a fraction of competitors (under $250 or employer-covered), bundled with free genetic counseling—disrupting a market gated by high costs and specialist waitlists.[1][2][3][5] Early traction included rapid global demand, $150M+ funding from Khosla Ventures, General Catalyst, and notables like Sundar Pichai and Laurene Powell-Jobs, plus pivotal NIH All of Us partnerships for genomic analysis and counseling for 1M participants.[1][2][5][6] By 2017-2018, expansions to heart conditions and medication response solidified its evolution into population health and full cancer care programs with the American Cancer Society.[2][5]
Color rides the precision medicine wave, leveraging falling sequencing costs and AI-driven genomics to shift healthcare from reactive to proactive, especially for cancer (top global killer alongside heart disease).[1][2] Timing aligns with post-21st Century Cures Act funding for initiatives like All of Us, enabling longitudinal data from 1M diverse participants to fuel research and equity in underserved communities.[5][6] Market forces like employer-sponsored health benefits, rising cancer screening demands, and global demand (Africa to South America) favor its model, influencing ecosystems by standardizing accessible genomics, partnering with ACS/NIH, and exporting tech to international providers—accelerating early detection and mortality reductions worldwide.[2][3][5]
Color is poised to expand its cancer dominance into broader chronic disease prevention, scaling AI-enhanced programs and global partnerships amid genomics' maturation. Trends like multimodal data integration (genomics + wearables) and value-based care will amplify growth, potentially pushing valuation beyond $4.6B via acquisitions or IPO. Its influence may evolve from testing pioneer to ecosystem orchestrator, empowering populations against hereditary risks—just as it began by making the unreachable affordable for all.[1][2]
Color Genomics has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series B in September 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2017 | Fabric Technologies | $3.0M Seed | Bessemer Venture Partners | Bling Capital, BoxGroup, First Round Capital, Flybridge Capital Partners, General Catalyst, Glencrest Group, Gutter Capital, Andrew Wheeler, Independent, Jonathan Golden, Hans Tung, Quiet Capital, Spero Ventures, Trajectory Ventures, Derrick Li, Henry Kravis, Justin Timberlake, Scott Belsky, Wiley Cerilli, Kal Vepuri, Maveron, Red Sea Ventures, RGAx |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2016 | $45.0M Series B | Primitive Ventures, Tencent Holdings |
